Titre:
  • Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?
Auteur:Bonnefoi, H; Diebold-Berger, S; Therasse, P.; Hamilton, Andrew; Van de Vijver, Marc J; MacGrogan, G; Shepherd, L; Amaral, N; Duval, C; Drijkoningen, R; Larsimont, Denis; Piccart-Gebhart, Martine
Informations sur la publication:Annals of oncology, 14, 3, page (406-413)
Statut de publication:Publié, 2003-03
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Administration, Oral
Adult
Aged
Anthracyclines -- therapeutic use
Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Breast Neoplasms -- drug therapy
Breast Neoplasms -- pathology
Cyclin D1 -- biosynthesis
Cyclin D1 -- blood
Cyclophosphamide -- administration & dosage
Epirubicin -- administration & dosage
Female
Fluorouracil -- administration & dosage
Gene Expression Regulation, Neoplastic
Granulocyte Colony-Stimulating Factor -- administration & dosage
Humans
Immunohistochemistry
Infusions, Intravenous
Ki-67 Antigen -- analysis
Ki-67 Antigen -- biosynthesis
Middle Aged
Neoadjuvant Therapy
Predictive Value of Tests
Prognosis
Receptor, erbB-2 -- biosynthesis
Receptor, erbB-2 -- blood
Receptors, Estrogen -- analysis
Receptors, Estrogen -- biosynthesis
Receptors, Progesterone -- analysis
Receptors, Progesterone -- biosynthesis
Survival Analysis
Treatment Outcome
Tumor Markers, Biological -- analysis
Tumor Suppressor Protein p53 -- biosynthesis
Tumor Suppressor Protein p53 -- blood
Note générale:Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langue:Anglais
Identificateurs:urn:issn:0923-7534
info:pmid/12598346